Page 6 - செயல்பாட்டு மரபியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from செயல்பாட்டு மரபியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In செயல்பாட்டு மரபியல் Today - Breaking & Trending Today

From crude surgery to gene editing: how cancer treatments evolved over the years

A little more than
two centuries ago, an English novelist named Frances Burney endured a “terrible operation” to remove a tumour after having breast cancer diagnosed.
Burney spent more than 17 agonising minutes under the scalpel as her surgeon in Paris cut away at her breast – all without anaesthetic.
She was 58 when the mastectomy was performed and lived another three decades, a happy outcome that went against the terrible odds faced by cancer patients at the time.
Fast forward to today and the cancer treatments being contemplated by Prof Dan Peer at Tel Aviv University in Israel are as sophisticated and precisely targeted as the one Burney suffered was crude. ....

France General , Frances Burney , Sam Kulkarni , Professor Dan Peer Of Tel Aviv University , Laboratory Of Precision Nanomedicine , Prof Dan Peer At Tel Aviv University , Prof Dan Peer , Tel Aviv University , Precision Nanomedicine , Dan Peer , Tel Aviv , Professor Dan Peer , Prof Peer , Cart Cell , Functional Genomics , Cart Cells , Crispr Therapeutics , Daniel Bardsley , பிரான்ஸ் ஜநரல் , பிரான்சிஸ் பர்னி , சாம் குல்கர்னி , ப்ரொஃபெஸர் டான் பியர் ஆஃப் தொலைபேசி அவிவ் பல்கலைக்கழகம் , ப்ரொஃப் டான் பியர் இல் தொலைபேசி அவிவ் பல்கலைக்கழகம் , ப்ரொஃப் டான் பியர் , தொலைபேசி அவிவ் பல்கலைக்கழகம் , டான் பியர் ,

Athersys Announces CEO Transition

Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage. ....

University Of Chicago , United States , United Kingdom , University Of Cape Town , Western Cape , South Africa , Washington University , South Australia , Van Bokkelen , Gil Van Bokkelen , Williambj Lehmann , Goodrich Rosati , Ivor Macleod , John Harrington , Ondek Pty Ltd , Corporate Communications Investor Relations , Russo Partners , University Of South Africa , Human Disease At Monash Medical School , Cambridge University , Early Clinical Research Experimental Medicine At Schering , Plough Research Institute , Monash University Medical School , First Chicago Corporation , Rhodes University , Nuffield School Of Medicine ,

Homegrown coronavirus variants are on the rise in the U.S. How worried should Americans be?

Homegrown coronavirus variants are on the rise in the U.S. How worried should Americans be?
Andrew Romano
© Provided by Yahoo! Lifestyle
In recent weeks, Americans have been waiting with bated breath for the arrival of worrisome overseas variants of SARS-CoV-2 the coronavirus that causes COVID-19.
We’ve all heard of B.1.1.7 (the so-called U.K. variant), B.1.351 (the so-called South Africa variant) and P.1 (the so-called Brazil variant). We’re dimly aware of how they work, with various spike-protein mutations that confer certain advantages, making them more transmissible (like B.1.1.7) or more likely to evade our immune defenses (like B.1.351 or P.1). We know that some cases have already been detected in the U.S., and that many more have likely gone undetected. And we worry that the more they spread here, the harder it will be to end the pandemic. ....

South Africa , United States , Mission Hills , Providence Holy Cross Medical Center , Los Angeles , Ariana Drehsler Bloomberg , Karwai Tang Getty , Jasmine Plummer , Jason Armond Los Angeles , News Health , Sinai Center , Getty Images , Cedars Sinai Center , Functional Genomics , Southern California , Yahoo News , Los Angeles Times , ஒன்றுபட்டது மாநிலங்களில் , பணி மலைகள் , ப்ராவிடெந்ஸ் பரிசுத்த குறுக்கு மருத்துவ மையம் , லாஸ் ஏஞ்சல்ஸ் , கர்வாய் டாங் கெட்டி , மல்லிகை ப்லமர் , ஜேசன் ஆர்மண்ட் லாஸ் ஏஞ்சல்ஸ் , செய்தி ஆரோக்கியம் , சினை மையம் ,

CRISPR and CAS Gene Market to Score Past US$ 7,603.8 Million Valuation by 2027: CMI – KSU

CRISPR and CAS Gene Market to Score Past US$ 7,603.8 Million Valuation by 2027: CMI – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Asia Pacific , Broad Institute , Transposagen Biopharmaceuticals Inc , Origene Technologies Inc , Agilent Technologies , Caribou Biosciences Inc , Harvard University , Takara Bio Inc , San Raffaele Telethon Institute For Gene Therapy , Stemcell Inc , Bayer Ag , Massachusetts Institute Of Technology , Cellecta Inc , Contract Research Organizations , Mirus Bio , Technologies Inc , Thermo Fisher Scientific Inc , Academic Government Research Institutes , Product Type , Vector Based Cas , Genome Engineering , Functional Genomics , End User , Pharmaceutical Companies ,

Researchers identify existing drug's potential for triple negative breast cancer

Researchers identify existing drug’s potential for triple negative breast cancer
28th January 2021
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).
The study, funded by research and care charity Breast Cancer Now, suggests that palbociclib – marketed by Pfizer as Ibrance – could be used to treat around a fifth of people with TNBC.
The research discovered a way to identify TNBC tumours that could be more likely to respond to CDK4/6 inhibitors such as palbociclib.
To do this, the research team screened 200 of the most frequently altered genes in breast cancer, to evaluate how changes in these genes affect a cancer’s ability to grow. ....

United Kingdom , City Of , Rachael Natrajan , Team Leader In Functional Genomics , Institute Of Cancer Research , Cancer Research , Breast Cancer Now , Team Leader , Functional Genomics , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ரேசல் நத்ராஜன் , அணி தலைவர் இல் செயல்பாட்டு மரபியல் , நிறுவனம் ஆஃப் புற்றுநோய் ஆராய்ச்சி , புற்றுநோய் ஆராய்ச்சி , மார்பக புற்றுநோய் இப்போது , அணி தலைவர் , செயல்பாட்டு மரபியல் ,